Before fluorouracil or capecitabine treatment, a germline genetic result can identify an important vulnerability: reduced ability to break down the drug. DPYD testing addresses treatment safety rather than tumour sensitivity. Its clinical value depends on understanding both a detected variant and the limits of a result in which no tested variant is found.
Connect the gene to drug handling
DPYD encodes dihydropyrimidine dehydrogenase, usually shortened to DPD. This enzyme breaks down more than 80% of fluorouracil. Certain variants reduce or abolish enzyme activity, increasing susceptibility to serious toxicity. Partial deficiency can increase risk; complete or near-complete deficiency creates particular concern for early, life-threatening reactions. These can include mucositis, diarrhoea, neutropenia and neurological toxicity. The FDA safety communication describes this relationship for fluorouracil and capecitabine.
A person can have DPD deficiency without an obvious clinical history. Absence of neurological symptoms or previous illness therefore does not establish normal drug metabolism. MedlinePlus Genetics explains that otherwise asymptomatic people may first become clinically vulnerable when exposed to fluoropyrimidines.
Separate pharmacogenetic risk from recessive disease
DPD deficiency also has a rare inherited presentation involving neurological and developmental problems. Its severity varies, and some people with two affected gene copies remain asymptomatic. The relationship between the biochemical abnormalities and neurological manifestations is incompletely understood. A pharmacogenetic result should therefore be explained in terms of the question it answers, without automatically assigning a neurological prognosis. MedlinePlus describes this clinical variability.
The recessive inheritance of the metabolic disorder can cause confusion in prescribing discussions. A person with one altered DPYD copy may still have increased susceptibility to fluoropyrimidine toxicity. Calling someone a carrier does not adequately communicate that treatment implication. Conversely, a drug-response finding alone does not establish that the person has the severe childhood disorder. The inheritance summary explicitly distinguishes these possibilities.
Read the assay scope before interpreting a negative result
Many clinical assays examine a selected set of four well-studied DPYD variants. Such testing does not examine every possible change in the gene. A report showing none of the tested variants therefore leaves residual genetic risk, as well as the other causes of chemotherapy toxicity. The NHS Genomics Education Programme emphasises that individual clinical factors and drug interactions remain relevant.
A practical report review should establish:
- Which variants the laboratory tested.
- Whether the result describes a genotype, predicted enzyme function or both.
- What limitations apply when no tested variant is detected.
These questions help prevent a limited negative result from becoming a blanket statement that treatment is safe. The same NHS resource notes that standard targeted testing identifies only a proportion of early life-threatening toxicity. Clinical observation remains essential regardless of the genetic result. See its testing limitations.
Make the result usable before prescribing
The FDA advises testing for DPYD variants before starting capecitabine or fluorouracil unless immediate treatment is necessary. Its communication also recommends avoiding these drugs in people with certain variant combinations causing complete deficiency, while describing individualised management for partial deficiency. These are clinical safety considerations, rather than an experimental use of genomic information. Current FDA information should be read alongside the applicable prescribing information.
For clinical implementation, the useful endpoint is a documented interpretation that reaches the treating team before the prescribing decision. Recording only that testing was ordered leaves the safety question unresolved. Patient discussions should connect the test to its purpose: identifying a preventable component of treatment risk while explaining that monitoring will still be needed.
Distinguish established use from further discovery
The established application concerns variants with evidence linking genotype, DPD function and fluoropyrimidine toxicity. Research can investigate additional variants, but detecting another DNA change does not itself establish a prescribing action. Broader testing and a better clinical decision are separate achievements: the latter requires reliable functional interpretation and clinical evidence. The NHS evidence summary anchors current practice in characterised variants and their treatment implications.